Clinical study on the treatment of adult hypertension (subacute liver and stomach fire hyperactivity syndrome) with Beijing made Niuhuang Jiedu tablets

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025001493

Enrollment

Unknown

Registered

2025-07-26

Start date

2025-08-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive urgencies

Interventions

Treatment group:Valsartan Amlodipine Tablets+Beijing made Niuhuang Detoxification Tablets

Control group:Valsartan Amlodipine Tablets

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for subacute hypertension; (2) Age range: 18-80 years old; (3) Meets the diagnostic criteria for liver and stomach fire hyperactivity syndrome; (4) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Individuals with severe secondary or primary illnesses; (2) Pregnant or lactating women; (3) Individuals allergic to the use of this medication; (4) Participated in another clinical trial in the past three months; (5) Individuals with spleen deficiency and diarrhea.

Design outcomes

Primary

Measure	Time frame
24-hour average nighttime systolic blood pressure;	—

Secondary

Measure	Time frame
Circadian rhythm of blood pressure;Traditional Chinese Medicine Syndrome Points;24-hour blood pressure variability;Clinical efficiency;Early morning hypertension incidence rate;Time within the target range of blood pressure;	—

Countries

China

Contacts

Public ContactFangxiaolei

Dongfang Hospital Beijing University of Chinese Medicine

fxl586@vip.sina.com18811412783

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026